Translating genomic analyses into improved management of coronary artery disease

Future Cardiology

Volumn 6, Issue 4, 2010, Pages 507-521

  Johansen, Christopher T ^a   Lanktree, Matthew B ^a   Hegele, Robert A ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

9p21; coronary artery disease; genetic risk prediction; genetic variation; genome wide association study; lifetime risk prediction; myocardial infarction

Indexed keywords

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; FAMILY HISTORY; FUTUROLOGY; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; FORECASTING; GENETIC PREDISPOSITION; GENETICS; RISK ASSESSMENT;

CORONARY ARTERY DISEASE; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 77954491927     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.28     Document Type: Review

References (110)

1. Roy H, Bhardwaj S, Yla-Herttuala S: Molecular genetics of atherosclerosis. Hum. Genet. 125(5-6), 467-491 (2009).
2. Lusis AJ, Fogelman AM, Fonarow GC: Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation 110(13), 1868-1873 (2004).
3. Yamada Y, Ichihara S, Nishida T: Molecular genetics of myocardial infarction. Genomic Med. 2(1-2), 7-22 (2008).
4. Tousoulis D, Briasoulis A, Papageorgiou N, Antoniades C, Stefanadis C: Candidate gene polymorphisms and the 9p21 locus in acute coronary syndromes. Trends Mol. Med. 14(10), 441-449 (2008).
5. Hegele RA: SNP judgments and freedom of association. Arterioscler. Thromb. Vasc. Biol. 22(7), 1058-1061 (2002).
6. Lander ES, Linton LM, Birren B et al.: Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001).
7. Frazer KA, Ballinger DG, Cox DR et al.: A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007).
8. Conrad DF, Pinto D, Redon R et al.: Origins and functional impact of copy number variation in the human genome. Nature 464(7289), 704-712 (2010).
9. Frazer KA, Murray SS, Schork NJ, Topol EJ: Human genetic variation and its contribution to complex traits. Nat. Rev. Genet. 10(4), 241-251 (2009).
10. Hurles ME, Dermitzakis ET, Tyler-Smith C: The functional impact of structural variation in humans. Trends Genet. 24(5), 238-245 (2008).
11. Redon R, Ishikawa S, Fitch KR et al.: Global variation in copy number in the human genome. Nature 444(7118), 444-454 (2006). (Pubitemid 44809057)
12. Attia J, Ioannidis JP, Thakkinstian A et al.: How to use an article about genetic association: A: background concepts. JAMA 301(1), 74-81 (2009).
13. Attia J, Ioannidis JP, Thakkinstian A et al.: How to use an article about genetic association: B: are the results of the study valid? JAMA 301(2), 191-197 (2009).
14. Attia J, Ioannidis JP, Thakkinstian A et al.: How to use an article about genetic association: C: what are the results and will they help me in caring for my patients? JAMA 301(3), 304-308 (2009).
15. Reich DE, Lander ES: On the allelic spectrum of human disease. Trends Genet. 17(9), 502-510 (2001).
16. Pritchard JK: Are rare variants responsible for susceptibility to complex diseases? Am. J. Hum. Genet. 69(1), 124-137 (2001).
17. Schork NJ, Murray SS, Frazer KA, Topol EJ: Common vs. rare allele hypotheses for complex diseases. Curr. Opin. Genet. Dev. 19(3), 212-219 (2009).
18. International HapMap Consortium: The international HapMap project. Nature 426(6968), 789-796 (2003).
19. Pearson TA, Manolio TA: How to interpret a genome-wide association study. JAMA 299(11), 1335-1344 (2008).
20. McPherson R, Pertsemlidis A, Kavaslar N et al.: A common allele on chromosome 9 associated with coronary heart disease. Science 316(5830), 1488-1491 (2007).
21. Helgadottir A, Thorleifsson G, Manolescu A et al.: A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316(5830), 1491-1493 (2007). (Pubitemid 46906618)
22. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447(7145), 661-678 (2007).
23. Broadbent HM, Peden JF, Lorkowski S et al.: Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum. Mol. Genet. 17(6), 806-814 (2008).
24. Holdt LM, Beutner F, Scholz M et al.: ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler. Thromb. Vasc. Biol. 30(3), 620-627 (2010).
25. Jarinova O, Stewart AF, Roberts R et al.: Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler. Thromb. Vasc. Biol. 29(10), 1671-1677 (2009).
26. Visel A, Zhu Y, May D et al.: Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 464(7287), 409-412 (2010).
27. Samani NJ, Erdmann J, Hall AS et al.: Genome-wide association analysis of coronary artery disease. N. Engl. J. Med. 357(5), 443-453 (2007). (Pubitemid 47204873)
28. Helgadottir A, Thorleifsson G, Magnusson KP et al.: The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat. Genet. 40(2), 217-224 (2008).
29. Schunkert H, Gotz A, Braund P et al.: Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation 117(13), 1675-1684 (2008).
30. Ye S, Willeit J, Kronenberg F, Xu Q, Kiechl S: Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. J. Am. Coll. Cardiol. 52(5), 378-384 (2008).
31. Thompson AR, Golledge J, Cooper JA et al.: Sequence variant on 9p21 is associated with the presence of abdominal aortic aneurysm disease but does not have an impact on aneurysmal expansion. Eur. J. Hum. Genet. 17(3), 391-394 (2009).
32. Abdullah KG, Li L, Shen GQ et al.: Four SNPs on chromosome 9p21 confer risk to premature, familial CAD and MI in an American Caucasian population (GeneQuest). Ann. Hum. Genet. 72(Pt 5), 654-657 (2008).
33. Muendlein A, Saely CH, Rhomberg S et al.: Evaluation of the association of genetic variants on the chromosomal loci 9p21.3, 6q25.1, and 2q36.3 with angiographically characterized coronary artery disease. Atherosclerosis 205(1), 174-180 (2009).
34. Shen GQ, Li L, Rao S et al.: Four SNPs on chromosome 9p21 in a South Korean population implicate a genetic locus that confers high cross-race risk for development of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 28(2), 360-365 (2008).
35. Shen GQ, Rao S, Martinelli N et al.: Association between four SNPSs on chromosome 9p21 and myocardial infarction is replicated in an Italian population. J. Hum. Genet. 53(2), 144-150 (2008).
36. Zhou L, Zhang X, He M et al.: Associations between single nucleotide polymorphisms on chromosome 9p21 and risk of coronary heart disease in Chinese Han population. Arterioscler. Thromb. Vasc. Biol. 28(11), 2085-2089 (2008).
37. Assimes TL, Knowles JW, Basu A et al.: Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic advance study. Hum. Mol. Genet. 17(15), 2320-2328 (2008).
38. Teo YY, Small KS, Kwiatkowski DP: Methodological challenges of genome-wide association analysis in Africa. Nat. Rev. Genet. 11(2), 149-160 (2010).
39. Cluett C, McDermott MM, Guralnik J et al.: The 9p21 myocardial infarction risk allele increases risk of peripheral artery disease in older people. Circ. Cardiovasc. Genet. 2(4), 347-353 (2009).
40. Bjorck HM, Lanne T, Alehagen U et al.: Association of genetic variation on chromosome 9p21.3 and arterial stiffness. J. Intern. Med. 265(3), 373-381 (2009).
41. Lemmens R, Abboud S, Robberecht W et al.: Variant on 9p21 strongly associates with coronary heart disease, but lacks association with common stroke. Eur. J. Hum. Genet. 17(10), 1287-1293 (2009).
42. Samani NJ, Raitakari OT, Sipila K et al.: Coronary artery disease-associated locus on chromosome 9p21 and early markers of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28(9), 1679-1683 (2008).
43. Wahlstrand B, Orho-Melander M, Delling L et al.: The myocardial infarction associated CDKN2A/CDKN2B locus on chromosome 9p21 is associated with stroke independently of coronary events in patients with hypertension. J. Hypertens. 27(4), 769-773 (2009).
44. Karvanen J, Silander K, Kee F et al.: The impact of newly identified loci on coronary heart disease, stroke and total mortality in the MORGAM prospective cohorts. Genet. Epidemiol. 33(3), 237-246 (2009).
45. Cunnington MS, Mayosi BM, Hall DH et al.: Novel genetic variants linked to coronary artery disease by genome-wide association are not associated with carotid artery intima-media thickness or intermediate risk phenotypes. Atherosclerosis 203(1), 41-44 (2009).
46. Smith JG, Melander O, Lovkvist H et al.: Common genetic variants on chromosome 9p21 confers risk of ischemic stroke: a large-scale genetic association study. Circ. Cardiovasc. Genet. 2(2), 159-164 (2009).
47. Lanktree MB, Hegele RA, Yusuf S, Anand SS: Multi-ethnic genetic association study of carotid intima-media thickness using a targeted cardiovascular SNP microarray. Stroke 40(10), 3173-3179 (2009).
48. Kathiresan S, Voight BF, Purcell S et al.: Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat. Genet. 41(3), 334-341 (2009).
49. Willer CJ, Sanna S, Jackson AU et al.: Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40(2), 161-169 (2008).
50. Linsel-Nitschke P, Heeren J, Aherrahrou Z et al.: Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis 208(1), 183-189 (2010).
51. Jansen P, Giehl K, Nyengaard JR et al.: Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat. Neurosci. 10(11), 1449-1457 (2007).
52. Nielsen MS, Jacobsen C, Olivecrona G, Gliemann J, Petersen CM: Sortilin/ neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase. J. Biol. Chem. 274(13), 8832-8836 (1999).
53. Nilsson SK, Christensen S, Raarup MK et al.: Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families. J. Biol. Chem. 283(38), 25920-25927 (2008).
54. Schadt EE, Molony C, Chudin E et al.: Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6(5), E107 (2008).
55. Hegele RA: Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet. 10(2), 109-121 (2009).
56. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354(12), 1264-1272 (2006).
57. Erdmann J, Grosshennig A, Braund PS et al.: New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat. Genet. 41(3), 280-282 (2009).
58. Kathiresan S, Willer CJ, Peloso GM et al.: Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41(1), 56-65 (2009).
59. Tregouet DA, Konig IR, Erdmann J et al.: Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat. Genet. 41(3), 283-285 (2009).
60. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG: Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 117(2), 176-184 (2008).
61. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG: Pentanucleotide repeat polymorphism, lipoprotein(a) levels, and risk of ischemic heart disease. J. Clin. Endocrinol. Metab. 93(10), 3769-3776 (2008).
62. Erqou S, Kaptoge S, Perry PL et al.: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302(4), 412-423 (2009).
63. Koschinsky ML, Marcovina SM: Structure- function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr. Opin. Lipidol. 15(2), 167-174 (2004).
64. Koschinsky ML: Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein. Curr. Atheroscler. Rep. 7(5), 389-395 (2005).
65. Sharrett AR, Ballantyne CM, Coady SA et al.: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 104(10), 1108-1113 (2001).
66. Lanktree MB, Anand SS, Yusuf S, Hegele RA: Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ. Cardiovasc. Genet. 3(1), 39-46 (2010).
67. Boerwinkle E, Leffert CC, Lin J et al.: Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90(1), 52-60 (1992).
68. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG: Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301(22), 2331-2339 (2009).
69. Clarke R, Peden JF, Hopewell JC et al.: Genetic variants associated with LP(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361(26), 2518-2528 (2009).
70. Samani NJ, Deloukas P, Erdmann J et al.: Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 29(5), 774-780 (2009).
71. Lanktree MB, Hegele RA: Gene-gene and gene-environment interactions: new insights into the prevention, detection and management of coronary artery disease. Genome Med. 1(2), 28 (2009).
72. Wilson PW, D'Agostino RB, Levy D et al.: Prediction of coronary heart disease using risk factor categories. Circulation 97(18), 1837-1847 (1998).
73. Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297(6), 611-619 (2007).
74. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR: C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118(22), 2243-2251, 2244P following 2251 (2008).
75. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001).
76. Zethelius B, Berglund L, Sundstrom J et al.: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med. 358(20), 2107-2116 (2008).
77. Li S, Zhao JH, Luan J et al.: Cumulative effects and predictive value of common obesity-susceptibility variants identified by genome-wide association studies. Am. J. Clin. Nutr. 91(1), 184-190 (2010).
78. Lango H, Palmer CN, Morris AD et al.: Assessing the combined impact of 18 common genetic variants of modest effect sizes on Type 2 diabetes risk. Diabetes 57(11), 3129-3135 (2008).
79. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 27(2), 157-172; discussion 207-1112 (2008).
80. Johansen CT, Hegele RA: Predictive genetic testing for coronary artery disease. Crit. Rev. Clin. Lab. Sci. 46(5-6), 343-360 (2009).
81. Paynter NP, Chasman DI, Buring JE et al.: Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann. Intern. Med. 150(2), 65-72 (2009).
82. Talmud PJ, Cooper JA, Palmen J et al.: Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin. Chem. 54(3), 467-474 (2008).
83. Brautbar A, Ballantyne CM, Lawson K et al.: Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the atherosclerosis risk in communities study. Circ. Cardiovasc. Genet. 2(3), 279-285 (2009).
84. Kathiresan S, Melander O, Anevski D et al.: Polymorphisms associated with cholesterol and risk of cardiovascular events. N. Engl. J. Med. 358(12), 1240-1249 (2008).
85. Arnett DK, Baird AE, Barkley RA et al.: Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 115(22), 2878-2901 (2007).
86. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr et al.: Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 291(18), 2204-2211 (2004).
87. Murabito JM, Pencina MJ, Nam BH et al.: Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA 294(24), 3117-3123 (2005).
88. Michos ED, Vasamreddy CR, Becker DM et al.: Women with a low Framingham Risk Score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. Am. Heart J. 150(6), 1276-1281 (2005).
89. Taraboanta C, Wu E, Lear S et al.: Subclinical atherosclerosis in subjects with family history of premature coronary artery disease. Am. Heart J. 155(6), 1020.E1-1026.E1 (2008).
90. Choi JC, Lee JS, Kang SY, Kang JH, Bae JM: Family history and risk for ischemic stroke: sibling history is more strongly correlated with the disease than parental history. J. Neurol. Sci. 284(1-2), 29-32 (2009).
91. Nasir K, Budoff MJ, Wong ND et al.: Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 116(6), 619-626 (2007).
92. Wang TJ, Nam BH, D'Agostino RB et al.: Carotid intima-media thickness is associated with premature parental coronary heart disease: the Framingham Heart Study. Circulation 108(5), 572-576 (2003).
93. Myers RH, Kiely DK, Cupples LA, Kannel WB: Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am. Heart J. 120(4), 963-969 (1990).
94. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS: Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 119(24), 3078-3084 (2009).
95. Tuzcu EM, Kapadia SR, Tutar E et al.: High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103(22), 2705-2710 (2001).
96. Bennet AM, Di Angelantonio E, Ye Z et al.: Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298(11), 1300-1311 (2007).
97. Linsel-Nitschke P, Gotz A, Erdmann J et al.: Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease - a Mendelian randomisation study. PLoS One 3(8), E2986 (2008).
98. Kraft P, Hunter DJ: Genetic risk prediction - are we there yet? N. Engl. J. Med. 360(17), 1701-1703 (2009).
99. Metzker ML: Sequencing technologies - the next generation. Nat. Rev. Genet. 11(1), 31-46 (2010).
100. Cohen JC, Pertsemlidis A, Fahmi S et al.: Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl Acad. Sci. USA 103(6), 1810-1815 (2006).
101. Cohen JC, Kiss RS, Pertsemlidis A et al.: Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305(5685), 869-872 (2004).
102. Romeo S, Pennacchio LA, Fu Y et al.: Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet. 39(4), 513-516 (2007).
103. Romeo S, Yin W, Kozlitina J et al.: Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119(1), 70-79 (2009).
104. Wang J, Cao H, Ban MR et al.: Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler. Thromb. Vasc. Biol. 27(11), 2450-2455 (2007).
105. Mangravite LM, Wilke RA, Zhang J, Krauss RM: Pharmacogenomics of statin response. Curr. Opin. Mol. Ther. 10(6), 555-561 (2008).
106. Pollex RL, Hegele RA: Copy number variation in the human genome and its implications for cardiovascular disease. Circulation 115(24), 3130-3138 (2007).
107. Tracy RP: 'Deep phenotyping': characterizing populations in the era of genomics and systems biology. Curr. Opin. Lipidol. 19(2), 151-157 (2008).
108. Lanktree MB, Hassell RG, Lahiry P, Hegele RA: Phenomics: expanding the role of clinical evaluation in genomic studies. J. Investig. Med. 58(5), 700-706 (2010).
109. Davey Smith G, Ebrahim S: 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32(1), 1-22 (2003).
110. International HapMap Consortium website http://hapmap.ncbi.nlm.nih.gov/ guidelines- hapmap-data.html